Rakuten Medical, Inc., a global biotechnology company developing and commercializing precision, cell-targeting Alluminox platform-based photoimmunotherapy, announced that it has completed the transfer of manufacturing technology from LI-COR Biosciences (LI-COR) for IRDye 700DX (IR700), a light-activatable dye. IR700 is a pivotal component of the Alluminox™ platform.
HealthTech Insights: IEHP Launches Program to Improve Patient-Provider Communication
Rakuten Medical is currently developing drug conjugates using IR700 and cell-targeting moieties. IR700 is activated by direct illumination with 690 nm light to selectively disrupt targeted cell membranes. The Company acquired the intellectual property, manufacturing technology, marketing rights, and all associated data for IR700 from LI-COR in December 2020. With the successful completion of the technology transfer, Rakuten Medical now serves as the sole owner and exclusive manufacturer & supplier of IR700. Through its capabilities for in-house production and supply, Rakuten Medical stands ready to strategically partner with companies, universities, and research institutions that are utilizing it in their therapeutic modalities.
HealthTech Insights: Wellstar MCG Health Providing Hospital-Level Care at Patients’ Homes
IR700, a dye derived from phthalocyanine, is distinguished by its hydrophilic structure, low toxicity, and light activation properties at a wavelength of 690 nm 1. Since light at approximately 690 nm can penetrate tissues to a certain depth, IR700 is suitable for various light-based therapies, including photoimmunotherapy. Its applications range from basic research in academia to clinical trials by biotech companies, including late-stage pipelines for various diseases such as ocular melanoma and bladder cancer. However, the complex and sensitive nature of IR700’s structure requires strict control over its synthesis, mass production, conjugation manufacturing, and rigorous quality assurance process.
HealthTech Insights: MyFitnessPal Launches Weekly Habits: Progress Made Simple, One Week at a Time
Mickey Mikitani, Chief Executive Officer and Vice Chairman of the Board of Rakuten Medical, commented, “IR700 is a unique, high-potential asset, playing a vital role in the Alluminox™ platform-based photoimmunotherapy and other therapeutic technologies. By achieving complete in-house manufacturing and exclusive supply of IR700, we have further enhanced both our technology platform and business foundation. Moving forward, we will strategically pursue partnerships with organizations that align with our values to drive the advancement of IR700-related therapeutic technologies, extending beyond the Alluminox™ platform and potentially contributing to the treatment of a broader range of patients worldwide.”
To participate in our inerviews, please write to our HealthTech Media Room at news@intentamplify.com
Source: PR Newswire
